Hydroxychloroquine
- PDF / 170,696 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 93 Downloads / 175 Views
1 S
Hydroxychloroquine Worsening of haemolytic crisis: case report
A 68-year-old man developed a worsening of haemolytic crisis during off-label treatment with hydroxychloroquine for Coronavirus disease (COVID-19). The man presented to the hospital with muscular pain, fever, dyspnoea and tiredness, and was subsequently admitted to a hospital in Switzerland due to positive COVID-19 infection. His medical history was significant for stroke, high blood pressure, type 2 diabetes mellitus and chronic renal insufficiency (G2 stage). On day 1, according to the institutional protocol, he was started on off-label treatment with amoxicillin/clavulanic-acid [amoxicillin/clavulanate] 1.2g 4 times daily and admitted in the general internal medicine division. In view of the development of acute respiratory distress syndrome and rapid respiratory degradation on day 3, his amoxicillin/clavulanic-acid treatment was switched to piperacillin/tazobactam. Later, he was transferred to the ICU and required mechanical ventilation. On day 6, according to the institutional protocol, he was started on off-label treatment with a single dose of hydroxychloroquine 600mg [route not stated]. However, during admission, he developed a significant drop in haemoglobin from 12 g/dL to 6.5 g/dL on day 1 and day 6, respectively. The man was treated with several blood transfusions. Further investigations excluded digestive spoliation. Blood workup showed a marked elevation in total and direct bilirubin and lactate dehydrogenase levels from day 5 along with biological signs of haemolysis. Numerous hemi-ghost cells and microspherocytes were observed in peripheral blood smear analysis, which indicated an acute haemolytic crisis in the context of an unknown glucose-6-phosphate dehydrogenase (G6PD) deficiency [duration of treatment to reaction onset not stated]. Further review of the daily blood smears analysis report suggested an appearance of hemighost cells and microspherocytes started from day 4 and slowly increased until day 7. Further investigation also confirmed a diagnosis of G6PD. However, it was also noted that the worsening of haemolytic crisis occurred on the next day of administration of hydroxychloroquine. Also, he did not take any medication, which could precipitated haemolysis. Based on the presenting symptoms and these findings, it was concluded that his severe COVID-19 infection triggered a haemolysis crisis with G6PD deficiency, which was possibly worsened by hydroxychloroquine therapy [outcome not stated]. Beauverd Y, et al. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. European Journal of Haematology 105: 357-359, No. 3, Sep 2020. Available from: URL: http://doi.org/10.1111/ejh.13432
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803500578
Reactions 12 Sep 2020 No. 1821
Data Loading...
